Drug Delivery

Other Drug Delivery Devices

Dose, formulation, and stability testing for non-standard drug delivery formats.

Controlled actuation, collection fixtures, environmental conditioning, and HPLC, ELISA, qPCR, or ddPCR quantitation matched to the device and formulation.

ISO 17025USP <601>ICH Q1AReviewed 2026-10-20
Request a quoteSubmit a sample

Testing specialty drug delivery devices

Specialty drug delivery device testing helps teams evaluate emerging, custom, or accessory-driven formats that do not fit cleanly into an inhaler, nebulizer, nasal spray, or package category. USP <601>, FDA drug-device guidance, and ICH Q1A provide context for common endpoints: emitted dose, formulation behavior, and stability-linked performance. Teams use this testing when:

  1. USP <601> dose collection compares emitted output across custom actuators, reservoirs, fill levels, or operating modes before design lock.
  2. FDA drug-device planning needs formulation-device compatibility data tied to HPLC, ELISA, qPCR, or ddPCR assay recovery.
  3. ICH Q1A storage pulls track API, impurity, dose, and device-function drift after temperature, humidity, or transport stress.
  4. Product-specific USP <601> or ISO 20072 concepts guide fit-for-purpose actuation, collection, and dose-uniformity setup for unusual delivery geometries.

ARE Labs plans testing around the decision the data must support. The plan defines the fixture, actuation sequence, collection endpoint, assay, and stability condition. USP <1601> applies to pulmonary products for nebulization; it is not the general method reference for this device category.

Core test menu for specialty delivery devices

Most non-standard delivery programs start with dose output, formulation support, and stability trending. Add aerosol sizing only when the route or claim makes particle size a material endpoint.

Test method options

MethodStrengthsTradeoffAligned with
Fit-for-purpose emitted dose and uniformity
  • Custom collection fixtures quantify emitted dose, delivered dose, and device-to-device variability under USP <601> logic.
  • Assay recovery links collected output to active-specific HPLC, ELISA, qPCR, or ddPCR results.
Fixture feasibility and extraction recovery must be resolved before pivotal dose comparisons can be interpreted.
USP <601>
Formulation-device compatibility screen
  • Formulation screens compare excipients, solvents, suspensions, powders, or process variables against ICH Q8/Q9/Q10 development logic.
  • Paired chemistry and output data identify adsorption, viscosity, settling, degradation, or delivery-loss drivers.
Screening narrows candidates; it does not replace final device verification or clinical performance evidence.
ICH Q8/Q9/Q10
Stability-linked performance and chemistry pulls
  • ICH Q1A pull points connect storage condition, API drift, impurity profile, and dose output in one study file.
  • Post-stress testing can compare pre/post device behavior after conditioning or transport exposure.
Study duration follows storage design; method feasibility should be completed before samples enter conditioning.
ICH Q1AASTM D4169
Route-dependent aerosol sizing add-on
  • PSD or APSD can be added when FDA route, deposition, inhalation, or exposure questions make particle size material.
  • Sizing data can be paired with dose or formulation outputs so screens remain tied to device performance.
Particle sizing is not automatically relevant; non-aerosol devices should stay focused on dose, chemistry, and stability.
FDA MDI / DPI / nasal

Setup configurations

Specialty drug delivery studies start with how the device works, rather than a preset method. During planning, we define what counts as one delivered use, where to collect output, how to actuate the device, which formulation variables matter, and how to handle storage or stress states. Those decisions set the replicate structure, assay plan, controls, and acceptance logic.

Device interfaces

Custom holders, adapters, reservoirs, mouthpiece or outlet fixtures, collection media, extraction vessels, and containment selected for the actual delivery geometry.

Actuation profiles

Force, stroke, timing, orientation, priming, fill level, dose count, dwell time, and user-step simulation documented per run.

Formulation state

Solution, suspension, powder, biologic, nucleic acid, solvent, preservative, viscosity, pH, osmolality, and handling state defined before testing.

Conditioning states

Temperature, humidity, transport stress, storage orientation, pull schedule, preconditioning, and post-stress handling linked to the study question.

Controls & replicates

Device count, actuation count, blanks, media controls, comparators, and replicate count sized to expected variability and assay sensitivity.

Quality frame for specialty delivery studies

Before feasibility work starts, we define how the study will handle method control, compendial references, stability records, and final reporting. The quality anchors below guide those decisions.

  • ISO 17025AccreditedTraceable calibration, method control, data review, and uncertainty documentation.
  • USP <601>AccreditedCompendial dose and aerosol-performance logic applied where relevant.
  • ICH Q1AAlignedStorage conditions, pull timing, and stability trend interpretation.

Key data outputs & reporting

ARE Labs reports emitted-dose statistics, formulation chemistry, assay recovery, and stability trends alongside fixture notes and QA/QC controls. These endpoint-specific datasets connect the custom setup to measured performance. Reports are prepared for development review, method justification, change control, or regulatory-support files. Programs that include comparability, transport stress, or stability pulls receive additional deliverables documenting those parts of the study.

Primary outputs

  • Emitted dose, delivered dose, shot-to-shot variability, device-to-device variability, and condition-based summary statistics.
  • Assay, impurity, recovery, pH, osmolality, formulation observation, and compatibility data where chemistry endpoints are included.
  • Stability pull-point tables and trend plots comparing pre/post conditioning, storage, or stress states.
  • Fixture, actuation, collection, extraction, calibration, control, and deviation records tied to each reported endpoint.

Deliverables

#FormatContents
01PDF reportMethods, setup, controls, deviations, results, and interpretation limits.
02CSV / XLSX datasetsDose statistics, chemistry tables, stability pulls, and condition summaries.
03FiguresTrend plots, pre/post comparisons, and setup diagrams when useful.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Comparability appendix — Side-by-side dose, chemistry, and condition summaries for reference or design-change review.
  • Stability trend pack — Pull-point tables and figures showing dose, assay, impurity, and device-function drift.
  • Transport-stress note — Conditioning exposure, handling observations, and post-stress performance changes summarized for packaging decisions.

QA / QC & data integrity

Custom device studies need QA/QC rules before the fixture is built. We run controls alongside sample collection to keep dose, chemistry, and stability data traceable from sample receipt through the final report. Method assumptions, invalid runs, storage state, assay suitability, and uncertainty contributors are documented in the study file.

Method blanks, collection-media controls, comparator devices, and condition controls defined by endpoint.

Balances, flow meters, chambers, timers, actuation fixtures, and analytical systems checked or calibrated before use.

HPLC, ELISA, qPCR, or ddPCR runs include standards, recovery checks, and suitability criteria where relevant.

Chain of custody covers devices, formulations, conditioned units, collected media, extracts, raw files, and analyst observations.

Predefined replicate rules, acceptance criteria, deviation handling, and outlier logic included in the protocol.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

These answers cover method selection, sample planning, formulation links, stability pulls, deliverables, and scope boundaries for specialty drug delivery devices that do not fit a standard inhaler, nebulizer, nasal, or package workflow. Most programs also need decisions about the fixture, collection approach, and assay during study planning. We define those study details before samples arrive at intake.

Q.How do we choose the first test?
A.Start with the decision you need to make. Dose testing measures output consistency, formulation support addresses composition and assay questions, and stability testing tracks changes during storage or stress. Add aerosol sizing only when particle size matters.
Q.Can ARE Labs build a custom fixture?
A.Yes. Specialty delivery studies often require custom holders, adapters, collection media, or actuation controls. Feasibility work confirms the setup before pivotal comparisons or stability pulls begin.
Q.Can formulation work be paired with dose testing?
A.Yes. Formulation screens can be paired with emitted dose, assay recovery, impurity checks, pH, osmolality, and physical observations to show how composition choices relate to device output.
Q.How many devices or actuations are needed?
A.We set device count, actuation count, fill states, storage pulls, and replicate count during protocol development. The plan depends on variability, assay sensitivity, and the decision the data must support.
Q.What data will I receive?
A.Deliverables can include dose statistics, chemistry tables, stability trend plots, setup notes, calibration and control records, deviations, a PDF report, and CSV or XLSX datasets.
Q.Does this cover complete regulatory approval?
A.No. ARE Labs supports defined testing and documentation, without claiming clinical testing, software validation, electrical safety, biocompatibility, product certification, or full submission management.

Standards & guidance

For other drug delivery devices, the delivery mechanism and the product's regulatory context guide study planning. ARE Labs reports accredited scopes as accredited and uses other references as aligned or conformant where applicable. The rows below cover dose output, formulation development, stability, and route-dependent aerosol characterization commonly cited in fit-for-purpose study plans.

Inhalation & Drug Delivery - Accredited

USP <601>

Dose collection and aerosol performance logic for inhalation and spray drug productsView standard ->QA & Regulatory - Aligned

ICH Q8/Q9/Q10

Pharmaceutical development, quality risk management, and formulation control strategyView standard ->QA & Regulatory - Aligned

ICH Q1A

Storage conditions, pull timing, and stability trend interpretation for drug productsView standard ->Packaging & Stability - Aligned

ASTM D4169

Distribution-cycle conditioning before post-stress device performance or package evaluationView standard ->QA & Regulatory - Aligned

FDA MDI / DPI / nasal

Quality considerations for inhalation and nasal drug products when route-dependent endpoints applyView standard ->

Related testing services

Test

Dose Uniformity & Emitted Dose

Core output test for custom drug delivery formats where actuation, fill state, reservoir design, or geometry may change delivered dose.Read more ->Test

Pharma Formulation Support

Pairs composition, excipient, process, and assay work with delivery performance for solution, suspension, powder, or biologic candidates.Read more ->Test

Stability and Accelerated Aging

Links storage, humidity, temperature, and transport stress to post-conditioning dose, chemistry, and device-function changes.Read more ->Test

Particle Size Distribution (PSD) Testing

Accurate add-on when the specialty device aerosolizes drug product and route, deposition, or exposure depends on particle size.Read more ->